Author

J. Kuball

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:human· 5 Research Focus:cell type annotation· 3 Research Focus:drug response / drug discovery· 3 Research Focus:cell-cell communication· 2 Research Focus:differential expression· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

Z. Sebestyen· 3 shared A. D. Meringa· 2 shared D. Beringer· 2 shared E. van Diest· 2 shared I. Johanna· 2 shared S. Heijhuurs· 2 shared S. Nierkens· 2 shared A. C. Rios· 1 shared

Activity by Year

2021-2024 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

Z. Sebestyen

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemia

F. Barneh, J. B. Koedijk, N. E. Wijnen, T. Meulendijks, M. Ashtiani, E. Dunnebach, N. Dautzenberg, A. M. Cornel, A. Krippner-Heidenreich, K. Klein, C. M. Zwaan, J. Kuball, S. Nierkens, J. Cloos, G. J. L. Kaspers, O. Heidenreich

This study evaluates CD19 expression in pediatric AML and shows that CD19-directed immunotherapies are effective against CD19+ AML, similar to their efficacy in BCP-ALL.

bioRxiv · Apr 19, 2024Immunology

Engineering BCMA CAR T cells for myeloma-targeted cargo delivery

T. Kimman, M. Cuenca, A. Slomp, R. G. Tieland, D. Rockx-Brouwer, S. Heijhuurs, A. D. Meringa, W. Boschloo, D. M. Bosma, S. Kroos, V. lo Presti, S. Nierkens, N. Bovenschen, J. Kuball, M. C. Minnema, , V. Peperzak

This paper develops BCMA CAR T cells with a granzyme B-NOXA fusion to enhance apoptosis in multiple myeloma cells, improving killing efficacy in vitro and in xenograft models.

bioRxiv · Feb 14, 2024 · PreprintImmunology

Challenges of γ9δ2TCR affinity maturation when using phage display

L. Kramer, M. Demuysere, E. van Diest, D. Beringer, J. Kuball

This study attempts to enhance the functional avidity of γ9δ2TCR through affinity maturation using phage display but fails due to instability of the scTCR format in bacterial expression.

bioRxiv · May 20, 2021 · PreprintImmunology

Behavioral-transcriptomic landscape of engineered T cells targeting human cancer organoids

J. F. Dekkers, M. Alieva, A. Cleven, F. Keramati, P. Brazda, H. G. Rebel, A. K. L. Wezenaar, J. Puschhof, M.-B. Buchholz, M. Barrera Roman, I. Johanna, A. D. Meringa, D. Fasci, M. H. Geurts, H. C. R. Ariese, , A. C. Rios

The paper develops BEHAV3D, a 3D imaging-transcriptomics platform to study T cell behavior and molecular mechanisms in cancer organoids, identifying a super engager cluster with unique gene signatures and IFN-I priming capabilities.

bioRxiv · May 5, 2021Cancer Biology

Tumor-reactivity of d2 negative gdT cells and the role of the gdT cell receptor

S. van Dooremalen, A. Janssen, L. Bloemenkamp, A. Yonka, D. Beringer, J. Kuball

The paper investigates tumor-reactivity of {delta}2 negative {gamma}{delta}T cells and finds that tumor-reactivity is not solely mediated by the {delta}2 negative {gamma}{delta}TCR.

bioRxiv · Mar 17, 2021 · PreprintImmunology

Enhancing cancer targeting of γ9δ2TCR through modified NKG2D co-stimulation

P. Hernandez-Lopez, E. van Diest, I. Johanna, S. Heijhuurs, T. Straetemans, Z. Sebestyen, D. X. Beringer, J. Kuball

This paper improves the antitumor activity of TEG001 by co-expressing NKG2D-based chimeric co-receptors with the {gamma}{delta}TCR-Cl5.

bioRxiv · Jan 6, 2021 · PreprintImmunology